Teva

Teva(TEVJF)

Israel - Petach Tikva
Pharmaceutical2 H-1B visas (FY2023)
WebsiteLinkedInCareers Page

Focus: Small Molecules, Biologics

Teva is a life sciences company focused on Small Molecules, Biologics.

NeurologyCardiovascularOncologyInfectious DiseasesImmunology
Funding Stage
PUBLIC
Open Jobs
0

Products & Portfolio (9)

41 discontinued products not shown

ACARBOSE
acarbose
Post-LOE
ORAL · TABLET
CLINICAL PHARMACOLOGY Acarbose is a complex oligosaccharide that delays the digestion of ingested carbohydrates, thereby resulting in a smaller rise in blood glucose concentration following meals. As a consequence of plasma glucose reduction, acarbose tablets reduce levels of glycosylated hemoglobin in patients with type 2 diabetes mellitus. Systemic non-enzymatic protein glycosylation, as reflected by levels of glycosylated hemoglobin, is a function of average blood glucose concentration over time. Mechanism of Action In contrast to sulfonylureas, acarbose tablets do not enhance insulin secretion. The antihyperglycemic action of acarbose results from a competitive, reversible inhibition of pancreatic alpha-amylase and membrane-bound intestinal alpha-glucoside hydrolase enzymes. Pancreatic alpha-amylase hydrolyzes complex starches to oligosaccharides in the lumen of the small intestine, while the membrane-bound intestinal alpha-glucosidases hydrolyze oligosaccharides, trisaccharides, and disaccharides to glucose and other monosaccharides in the brush border of the small intestine. In diabetic patients, this enzyme inhibition results in a delayed glucose absorption and a lowering of postprandial hyperglycemia. Because its mechanism of action is different, the effect of acarbose tablets to enhance glycemic control is additive to that of sulfonylureas, insulin or metformin when used in combination. In addition, acarbose tablets diminish the insulinotropic and weight-increasing effects of sulfonylureas. Acarbose has no inhibitory activity against lactase and consequently would not be expected to induce lactose intolerance. Pharmacokinetics: Absorption In a study of 6 healthy men, less than 2% of an oral dose of acarbose was absorbed as active drug, while approximately 35% of total radioactivity from a 14C-labeled oral dose was absorbed. An average of 51% of an oral dose was excreted in the feces as unabsorbed drug-related radioactivity within 96 hours of ingestion. Because acarbose acts locally within the gastrointestinal tract, this low systemic bioavailability of parent compound is therapeutically desired. Following oral dosing of healthy volunteers with 14C-labeled acarbose, peak plasma concentrations of radioactivity were attained 14-24 hours after dosing, while peak plasma concentrations of active drug were attained at approximately 1 hour. The delayed absorption of acarbose-related radioactivity reflects the absorption of metabolites that may be formed by either intestinal bacteria or intestinal enzymatic hydrolysis. Metabolism Acarbose is metabolized exclusively within the gastrointestinal tract, principally by intestinal bacteria, but also by digestive enzymes. A fraction of these metabolites (approximately 34% of the dose) was absorbed and subsequently excreted in the urine. At least 13 metabolites have been separated chromatographically from urine specimens. The major metabolites have been identified as 4-methylpyrogallol derivatives (that
type 2 diabetes mellitus
2008
30
ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE
acetaminophen; oxycodone hydrochloride
Pre-Launch
ORAL · TABLET, EXTENDED RELEASE
Mechanism of Action Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and are thought to play a role in the analgesic effects of this drug. The precise mechanism of the analgesic properties of acetaminophen is not established but is thought to involve central actions.
pain severe enough to require an opioid analgesicfor which alternative treatments are inadequate
ACITRETIN
acitretin
Post-LOE
ORAL · CAPSULE
CLINICAL PHARMACOLOGY The mechanism of action of acitretin is unknown. Pharmacokinetics Absorption Oral absorption of acitretin is optimal when given with food. For this reason, acitretin was given with food in all of the following trials. After administration of a single 50-mg oral dose of acitretin to 18 healthy subjects, maximum plasma concentrations ranged from 196 to 728 ng per mL (mean: 416 ng per mL) and were achieved in 2 to 5 hours (mean: 2.7 hours). The oral absorption of acitretin is linear and proportional with increasing doses from 25 to 100 mg. Approximately 72% (range: 47% to 109%) of the administered dose was absorbed after a single 50-mg dose of acitretin was given to 12 healthy subjects. Distribution Acitretin is more than 99.9% bound to plasma proteins, primarily albumin. Metabolism (See , Ethanol .) Following oral absorption, acitretin undergoes extensive metabolism and interconversion by simple isomerization to its 13-cis form (cis-acitretin). The formation of cis-acitretin relative to parent compound is not altered by dose or fed/fast conditions of oral administration of acitretin. Both parent compound and isomer are further metabolized into chain-shortened breakdown products and conjugates, which are excreted. Following multiple-dose administration of acitretin, steady-state concentrations of acitretin and cis-acitretin in plasma are achieved within approximately 3 weeks. Elimination The chain-shortened metabolites and conjugates of acitretin and cis-acitretin are ultimately excreted in the feces (34% to 54%) and urine (16% to 53%). The terminal elimination half-life of acitretin following multiple-dose administration is 49 hours (range: 33 to 96 hours), and that of cis-acitretin under the same conditions is 63 hours (range: 28 to 157 hours). The accumulation ratio of the parent compound is 1.2; that of cis-acitretin is 6.6. Special Populations Psoriasis In an 8-week trial of acitretin pharmacokinetics in subjects with psoriasis, mean steady-state trough concentrations of acitretin increased in a dose-proportional manner with dosages ranging from 10 to 50 mg daily. Acitretin plasma concentrations were nonmeasurable (< 4 ng per mL) in all subjects 3 weeks after cessation of therapy. Elderly In a multiple-dose trial in healthy young (n = 6) and elderly (n = 8) subjects, a 2-fold increase in acitretin plasma concentrations were seen in elderly subjects, although the elimination half-life did not change. Renal Failure Plasma concentrations of acitretin were significantly (59.3%) lower in subjects with end-stage renal failure (n = 6) when compared with age-matched controls, following single 50-mg oral doses. Acitretin was not removed by hemodialysis in these subjects. Pharmacokinetic Drug Interactions (See also boxed AND and , ) In studies of in vivo pharmacokinetic drug interactions, no interaction was seen between acitretin and cimetidine, digoxin, phenprocoumon, or glyburide. Ethanol Clinical evidence has shown that etretinat
severe psoriasis in adultspsoriasis
2013
30
ACYCLOVIR
acyclovir
Post-LOE
ORAL · CAPSULE
CLINICAL PHARMACOLOGY Pharmacokinetics: The pharmacokinetics of acyclovir after oral administration have been evaluated in healthy volunteers and in immunocompromised patients with herpes simplex or varicella-zoster virus infection. Acyclovir pharmacokinetic parameters are summarized in Table 1. Table 1. Acyclovir Pharmacokinetic Characteristics (Range) Bioavailability decreases with increasing dose. Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2. The decrease in bioavailability is a function of the dose and not the dosage form. Table 2. Acyclovir Peak and Trough Concentrations at Steady State Parameter 200 mg 400 mg 800 mg C m a x 0.83 mcg/mL 1.21 mcg/mL 1.61 mcg/mL C t r o u g h 0.46 mcg/mL 0.63 mcg/mL 0.83 mcg/mL There was no effect of food on the absorption of acyclovir (n = 6); therefore, Acyclovir Tablets may be administered with or without food. The only known urinary metabolite is 9-[(carboxymethoxy)methyl]guanine. Special Populations: Adults With Impaired Renal Function: The half-life and total body clearance of acyclovir are dependent on renal function. A dosage adjustment is recommended for patients with reduced renal function ( ). Geriatrics: Acyclovir plasma concentrations are higher in geriatric patients compared with younger adults, in part due to age-related changes in renal function. Dosage reduction may be required in geriatric patients with underlying renal impairment ( ). Pediatrics: In general, the pharmacokinetics of acyclovir in pediatric patients is similar to that of adults. Mean half-life after oral doses of 300 mg/m and 600 mg/m in pediatric patients aged 7 months to 7 years was 2.6 hours (range 1.59 to 3.74 hours). Drug Interactions: Coadministration of probenecid with intravenous acyclovir has been shown to increase the mean acyclovir half-life and the area under the concentration-time curve. Urinary excretion and renal clearance were correspondingly reduced. Clinical Trials: Initial Genital Herpes: Double-blind, placebo-controlled studies have demonstrated that orally administered acyclovir significantly reduced the duration of acute infection and duration of lesion healing. The duration of pain and new lesion formation was decreased in some patient groups. Recurrent Genital Herpes: Double-blind, placebo-controlled studies in patients with frequent recurrences (6 or more episodes per year) have shown that orally administered acyclovir given daily for 4 months to 10 years prevented or reduced the frequency and/or severity of recurrences in greater than 95% of patients. In a study of patients who received acyclovir 400 mg twice daily for 3 years, 45%, 52%, and 63% of patients remained free of recurrences in the first, second, and thi
initial episodesthe management of recurrent episodes of genital herpeschickenpox (varicella)
1997
30
ACYCLOVIR
acyclovir
Post-LOE
ORAL · TABLET
CLINICAL PHARMACOLOGY Pharmacokinetics: The pharmacokinetics of acyclovir after oral administration have been evaluated in healthy volunteers and in immunocompromised patients with herpes simplex or varicella-zoster virus infection. Acyclovir pharmacokinetic parameters are summarized in Table 1. Table 1. Acyclovir Pharmacokinetic Characteristics (Range) Bioavailability decreases with increasing dose. Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20% In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2. The decrease in bioavailability is a function of the dose and not the dosage form. Table 2. Acyclovir Peak and Trough Concentrations at Steady State Parameter 200 mg 400 mg 800 mg C m a x 0.83 mcg/mL 1.21 mcg/mL 1.61 mcg/mL C t r o u g h 0.46 mcg/mL 0.63 mcg/mL 0.83 mcg/mL There was no effect of food on the absorption of acyclovir (n = 6); therefore, Acyclovir Tablets may be administered with or without food. The only known urinary metabolite is 9-[(carboxymethoxy)methyl]guanine. Special Populations: Adults With Impaired Renal Function: The half-life and total body clearance of acyclovir are dependent on renal function. A dosage adjustment is recommended for patients with reduced renal function ( ). Geriatrics: Acyclovir plasma concentrations are higher in geriatric patients compared with younger adults, in part due to age-related changes in renal function. Dosage reduction may be required in geriatric patients with underlying renal impairment ( ). Pediatrics: In general, the pharmacokinetics of acyclovir in pediatric patients is similar to that of adults. Mean half-life after oral doses of 300 mg/m and 600 mg/m in pediatric patients aged 7 months to 7 years was 2.6 hours (range 1.59 to 3.74 hours). Drug Interactions: Coadministration of probenecid with intravenous acyclovir has been shown to increase the mean acyclovir half-life and the area under the concentration-time curve. Urinary excretion and renal clearance were correspondingly reduced. Clinical Trials: Initial Genital Herpes: Double-blind, placebo-controlled studies have demonstrated that orally administered acyclovir significantly reduced the duration of acute infection and duration of lesion healing. The duration of pain and new lesion formation was decreased in some patient groups. Recurrent Genital Herpes: Double-blind, placebo-controlled studies in patients with frequent recurrences (6 or more episodes per year) have shown that orally administered acyclovir given daily for 4 months to 10 years prevented or reduced the frequency and/or severity of recurrences in greater than 95% of patients. In a study of patients who received acyclovir 400 mg twice daily for 3 years, 45%, 52%, and 63% of patients remained free of recurrences in the first, second, and thi
initial episodesthe management of recurrent episodes of genital herpeschickenpox (varicella)
1997
30
ACYCLOVIR
acyclovir
Post-LOE
SMORAL · SUSPENSION
DNA Polymerase Inhibitors
initial episodesthe management of recurrent episodes of genital herpeschickenpox (varicella)
1997
30
ADAPALENE
adapalene
Post-LOE
TOPICAL · GEL
12.1 Mechanism of Action Adapalene binds to specific retinoic acid nuclear receptors but does not bind to cytosolic receptor protein. Biochemical and pharmacological profile studies have demonstrated that adapalene is a modulator of cellular differentiation, keratinization, and inflammatory processes. However, the significance of these findings with regard to the mechanism of action of adapalene for the treatment of acne is unknown. 12.2 Pharmacodynamics Clinical pharmacodynamic studies have not been conducted for adapalene gel. 12.3 Pharmacokinetics Systemic exposure of adapalene following topical application of adapalene gel was evaluated in a clinical trial. Sixteen acne subjects were treated once daily for 10 days with 2 grams of adapalene gel applied to the face, chest and back, corresponding to approximately 2 mg/cm. Fifteen subjects had quantifiable (LOQ = 0.1 ng/mL) adapalene levels resulting in a mean C max of 0.553 ± 0.466 ng/mL on Day 10 of treatment. The mean AUC 0-24hr was 8.37 ± 8.46 ng.h/mL as determined in 15 of the 16 subjects on Day 10. The terminal apparent half-life, determined in 15 of 16 subjects, ranged from 7 to 51 hours, with a mean of 17.2 ± 10.2 hours. Adapalene was rapidly cleared from plasma and was not detected 72 hours after the last application for all but one subject. Exposure of potential circulating metabolites of adapalene was not measured. Excretion of adapalene appears to be primarily by the biliary route. In another clinical trial in subjects with moderate to moderately severe acne, adapalene gel, 0.3% or Adapalene Gel, 0.1% was applied to the face and optionally to the trunk, once daily for 12 weeks. Seventy-eight (78) subjects had plasma adapalene levels evaluated at Weeks 2, 8, and 12. Of the 209 plasma samples analyzed, adapalene concentrations were below the limit of detection (LOD = 0.15 ng/mL) of the method in all samples but three. For the three samples, traces of adapalene below the limit of quantification (LOQ = 0.25 ng/mL) of the method were found. One of these samples was taken at Week 12 from a male subject treated with adapalene gel who treated the face and the trunk for eight weeks (thereafter, only the face was treated). The second and third samples were from the Week 2 and 12 visits of a female subject treated with adapalene gel, 0.1% who treated only the face for 12 weeks. In this study, the average daily usage of product was 1 g/day.
2014
30
ADAPALENE AND BENZOYL PEROXIDE
adapalene and benzoyl peroxide
Post-LOE
TOPICAL · GEL
protein. Biochemical and pharmacological profile studies have demonstrated that adapalene is a modulator of cellular differentiation, keratinization and inflammatory processes. However, the significance of these findings with regard to the mechanism of action of adapalene for the treatment of acne is unknown. Benzoyl peroxide Benzoyl peroxide is an oxidizing agent with bactericidal and keratolytic effects.
2022
30
ADIPEX-P
phentermine hydrochloride
Post-LOE
ORAL · TABLET
obesity, amphetamine (d- and d l l-amphetamine). Drugs of this class used in obesity are commonly known as "anorectics" or "anorexigenics." It has not been established that the primary action of such drugs in treating obesity is one of appetite suppression since other central nervous system actions, or metabolic effects, may also be involved.
hypertension
1980
30

Pipeline & Clinical Trials

Extra-fine hydrofluoroalkane-beclomethasone dipropionate
Asthma
N/A
Clinical Trials (1)
NCT01141439Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management
N/A
Glatiramer acetate
Multiple Sclerosis
N/A
Clinical Trials (5)
NCT00203047Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate
Phase 4
NCT00337779Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).
Phase 3
NCT00666224Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome
Phase 3

+2 more

level of agitation
Psychiatric Issue
N/A
Clinical Trials (1)
NCT02713100Self Reported Level of Agitation of Patients Presenting to an Emergency Department
N/A
Fremanezumab
Migraine
N/A
Clinical Trials (1)
NCT03539393Fremanezumab Compassionate Use Program for Pediatric Patients
N/A
Mindfulness based stress reduction
Multiple Sclerosis
N/A
Clinical Trials (1)
NCT01419301Mindfulness Based Stress Reduction in Multiple Sclerosis (MS)
N/A
Bach's Rescue Remedy Cream
Multiple Sclerosis
N/A
Clinical Trials (1)
NCT00972062Herbal Therapy for Subcutaneous Injection Site Reactions in Multiple Sclerosis
N/A
Sleep Recording
Parkinson Disease
N/A
Clinical Trials (1)
NCT02907723Feasibility of Continuous Sleep Recording in Patients Undergoing Deep Brain Stimulation for Parkinson's Disease
N/A
Adenovirus Vaccine Pregnancy Registry
Adenovirus
N/A
Clinical Trials (1)
NCT01584037Adenovirus Vaccine Pregnancy Registry
N/A
NAbs testing
Multiple Sclerosis
N/A
Clinical Trials (1)
NCT00336557Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy
N/A
Modafinil/armodafinil
Narcolepsy
N/A
Clinical Trials (1)
NCT01792583The Nuvigil and Provigil Pregnancy Registry
N/A
Extra-fine hydrofluoroalkane-beclometasone dipropionate
Asthma
N/A
Clinical Trials (1)
NCT01697722Real-world Effectiveness and Cost-effectiveness of HFA-beclometasone Compared With ICS/LABA Combination Therapy
N/A
N/A
Clinical Trials (2)
NCT00937157Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)
N/A
NCT00203086A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis
N/A
Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months
Multiple Sclerosis
N/A
Clinical Trials (1)
NCT02017808Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months
N/A
Group R+AD Rasagiline + Antidepressant
Serotonin Syndrome
N/A
Clinical Trials (1)
NCT00955604Azilect + Antidepressant Chart Review
N/A
N/A
Clinical Trials (1)
NCT02809989A Study to Evaluate the Effect of Ovaleap® on the Pregnancy Rate and Clinical Effects as Well as the User-friendliness of the Ovaleap®-Pen.
N/A
Bradykinesia UPDRS Motor Full Examination
Parkinson's Disease
N/A
Clinical Trials (1)
NCT00932581Bradykinesia Subscale Administered Alone Versus Regular Administration: Psychometric Properties
N/A
N/A
Clinical Trials (1)
NCT01340781Screening Tools for Obstructive Sleep Apnea (OSA) in Hospitalized Medical Patients
N/A
N/A
Clinical Trials (1)
NCT05241288Digihaler in Chronic Obstructive Pulmonary Disease (COPD)
N/A
Budesonide, Formoterol Fumarate Dihydrate
Patient Satisfaction
N/A
Clinical Trials (1)
NCT02384577Study to Evaluate Satisfaction and Usability of DuoResp® SPIROMAX® in Asthma and COPD Treatment
N/A
N/A
Clinical Trials (1)
NCT02266121Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis
N/A
Prospective Observational Study in Patients With Metastatic Breast Cancer Treated With Anthracycline
Metastatic Breast Cancer
N/A
Clinical Trials (1)
NCT01555944Prospective Observational Study in Patients With Metastatic Breast Cancer Treated With Anthracyclines
N/A
Protocol Intervention Group
Huntington Disease
N/A
Clinical Trials (1)
NCT03417583Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Huntington's Disease Patients
N/A
Effentora®
Cancer
N/A
Clinical Trials (1)
NCT01400854Effentora® in Clinical Practice - a Non-interventional Study to Evaluate Satisfaction and Tolerability
N/A
Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effe
HIV Infections
N/A
Extra-fine hydrofluoroalkane beclometasone dipropionate
Asthma
N/A
Clinical Trials (1)
NCT01877954Qvar vs FP in Pediatrics
N/A
N/A
Clinical Trials (1)
NCT01733082The Mycophenolate Pregnancy Registry
N/A
formoterol
Asthma
N/A
Clinical Trials (2)
NCT05831566Expertise Asthma COPD Program with Digital Support
Phase 3
NCT00643578Dose-response of Inhaled Formoterol Using Methacholine Challenge as a Bioassay
N/A
Glatiramer Acetate, IFN-beta 1a
Multiple Sclerosis
N/A
Clinical Trials (1)
NCT00819000Therapy Optimization in Multiple Sclerosis (MS)
N/A
Correlation Between PET and Advanced MRI in Multiple Sclerosis
Multiple Sclerosis
N/A
Clinical Trials (1)
NCT02869360Correlation Between PET and Advanced MRI in Multiple Sclerosis
N/A
A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy
Multiple Sclerosis
N/A
Clinical Trials (1)
NCT00238654A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy
N/A
extra fine particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler
Asthma
N/A
Clinical Trials (1)
NCT01400217Qvar Versus Clenil, a General Practice Research Database Study
N/A
Fremanezumab
Migraine
N/A
Clinical Trials (1)
NCT07029126Improving the Perception of Stress and Mutuality in Caregivers (MI-DEAR Study) of Migraine Patients With Depressive Symptoms Treated With Fremanezumab: A Study to Evaluate Whether Fremanezumab Reduces the Impact on Caregivers and Increases Couple Reciprocity
N/A
Marketed antagonists
Asthma
N/A
Clinical Trials (1)
NCT02419872Study in Patients' With Persistent Asthma and Chronic Obstructive Pulmonary Disease
N/A
Naturalistic Adasuve Clinical Trial Study
Agitation
N/A
Clinical Trials (1)
NCT02877108Naturalistic Adasuve Clinical Trial Study
N/A
Rasagiline mesylate
Parkinson's Disease
N/A
Clinical Trials (1)
NCT01032486Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease
N/A
Qvar Therapy in Smoking Asthmatics
Asthma
N/A
Clinical Trials (1)
NCT01729351Qvar Therapy in Smoking Asthmatics
N/A
rasagiline mesylate
Parkinson's Disease
N/A
Clinical Trials (1)
NCT00936676ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
N/A
Digihaler Albuterol Device by TEVA
Asthma in Children
N/A
Clinical Trials (1)
NCT04896645Albuterol Integrated Adherence Monitoring in Children With Asthma
N/A
Glatiramer acetate
Multiple Sclerosis
N/A
Clinical Trials (1)
NCT03209479Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"
N/A
A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melano
Parkinson's Disease
N/A
Clinical Trials (1)
NCT00203008A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma
N/A
Systematic detection of vascular risk factors and subsequent evidence-based treatment
Stroke
N/A
Clinical Trials (1)
NCT01107548Prevention of Stroke and Dementia in Primary Care
N/A
N/A
Clinical Trials (2)
NCT02207387Ambulosono Rasagiline Musical Walking Study
N/A
NCT02384512Azilect® In Wearing-Off (AIWO)
N/A
Initiation of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device
Asthma
N/A
Clinical Trials (1)
NCT01313585Device Mixing in Asthma, a General Practice Research Database Study
N/A
Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Primary (CUP)
Neoplasms, Unknown Primary
N/A
Clinical Trials (1)
NCT01202786Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Primary (CUP)
N/A
The Ribavirin Pregnancy Registry
Birth Defects
N/A
Clinical Trials (1)
NCT00114712The Ribavirin Pregnancy Registry
N/A
Training on BF Spiromax followed by SYMBICORT Turbohaler
Asthma
N/A
Clinical Trials (1)
NCT02570425Comparing Maintenance of Device Mastery With Turbohaler© vs. Spiromax© in Healthcare Professionals naïve to Both Devices
N/A
Smoking
Asthma
N/A
Clinical Trials (1)
NCT02833727Airway Inflammation and Disease Burden in Asthmatic Smokers
N/A
ProAir Digihaler
COPD
N/A
Clinical Trials (1)
NCT04821869ProAir Digihaler in COPD Disease Management: A Real World Study
N/A
Immediate postpartum placement of IUD
Contraception
N/A
Clinical Trials (1)
NCT02024672Monitoring With Ultrasound Imaging of Intrauterine Device (IUD) Position Placed Immediately After Giving Birth
N/A
Clarithromycin
Healthy
Phase 1
Clinical Trials (2)
NCT00840216Clarithromycin 500 mg Extended Release Tablets Under Non-Fasting Conditions.
Phase 1
NCT00835692Clarithromycin 500 mg Tablets Under Fasting Conditions
Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 2426 approved products, 156 clinical trials
Top TAs: Neurology, Oncology, Cardiovascular
H-1B (2023): 2 approvals
SEC Filings: 2 available
Portfolio Health
Pre-Launch486 (20%)
Growth4 (0%)
Peak28 (1%)
LOE Approaching78 (3%)
Post-LOE1830 (75%)
2426 total products
Therapeutic Area Focus
Neurology
182 marketed132 pipeline
Oncology
54 marketed95 pipeline
Cardiovascular
127 marketed1 pipeline
Respiratory
33 marketed90 pipeline
Infectious Diseases
96 marketed5 pipeline
Immunology
58 marketed21 pipeline
Metabolic Diseases
27 marketed1 pipeline
Gastroenterology
24 marketed3 pipeline
Marketed
Pipeline

Financials (FY2025)

Revenue
$1.5B90%
R&D Spend
$953M(64%)14%
Net Income
-$559M
Cash
$3.2B
Source: SEC 10-K Filing

Hiring Trend

Stable
0
Open Roles
+0
Added
-0
Filled/Removed

Based on last 2 crawl cycles

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
2
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub